Lead Product(s): HM15211
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: Undisclosed
Highest Development Status: Phase I Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 28, 2020
Hanmi is planning to begin the global Phase 2 trials of LAPSTriple Agonist in the second quarter this year with biopsy-proven NASH patients.